Epithalon — also spelled Epitalon, and abbreviated AEDG — is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is one of the most discussed peptides in aging research, not because its biology is settled, but because of a striking set of early laboratory findings and a long, unusually concentrated body of work behind it. This guide summarizes what the published literature reports about Epithalon — and, just as importantly, where that evidence is still thin.
Epithalon did not begin as a designed molecule. It was derived from epithalamin, a peptide preparation extracted from the pineal gland (originally bovine). Researchers analyzed the amino-acid composition of that extract and synthesized a short, defined tetrapeptide intended to capture its putative active component — the result being Ala-Glu-Asp-Gly. The work was carried out by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, and it is worth knowing from the outset that a large share of the Epithalon literature originates from that same institution.
The pineal-gland origin matters for interpreting the research. The pineal gland is central to the body's circadian and melatonin signaling, and much of the interest in Epithalon has followed from the idea that a small peptide reflecting pineal chemistry might influence those same aging- and rhythm-related pathways in model systems.
The observation that put Epithalon on the map came from cell-culture work on telomerase — the enzyme that maintains the protective telomere caps at the ends of chromosomes. In a frequently cited 2003 study, adding Epithalon to telomerase-inactive human fetal fibroblasts was reported to induce expression of the enzyme's catalytic subunit, restore telomerase activity, and produce measurable telomere elongation, with treated cells continuing to divide beyond their usual passage limit in that experiment.
The important nuance, which marketing copy routinely drops: this was an in-vitro result in a specific cell model. Telomere biology is central to how researchers think about cellular aging, so a peptide that appears to nudge telomerase activity is genuinely interesting to study — but "raises telomerase in cultured cells" is a long way from any demonstrated effect on aging in a living human being. Later cell-line work has continued to examine how, and how consistently, Epithalon influences telomere length, including whether telomerase up-regulation is the only pathway involved.
Across in-vitro and animal-model studies, Epithalon and the parent epithalamin preparation have been associated with a range of activities. Each of the following is drawn from laboratory or preclinical research — none should be read as an established human clinical outcome, and effects are described only as observed in studies:
Much of Epithalon's reputation rests on longevity and anti-aging experiments: reports of extended lifespan in animal models and of physiological changes framed as "geroprotective." These are the findings that generate headlines, and they are also the findings that call for the most restraint.
Two facts should shape how the results are read. First, a great deal of the aging-related work on Epithalon and epithalamin was conducted by a single research group in St. Petersburg, which means independent, international replication is comparatively limited. Second, most of the strongest claims come from cell and animal models, not from large, controlled human clinical trials. That does not make the work uninteresting — it makes it preliminary. Responsible reading treats Epithalon's longevity data as early-stage research hypotheses, not as demonstrated anti-aging effects in people.
Epithalon is not an FDA-approved drug. In the United States it has, however, recently been part of the regulatory conversation around pharmacy compounding. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed a group of peptides — including Epitalon — as candidates for the section 503A bulk drug substances list, which governs what substances compounding pharmacies may use.
It is important to read that event precisely. The committee was not voting to approve Epithalon as a drug; as one panelist noted, the process was not designed to establish dosing, safety and efficacy the way a drug approval would. The panel voted narrowly in favor of adding Epitalon to the 503A list, but FDA staff had recommended against it, citing insufficient clinical evidence, and the FDA is not obligated to follow an advisory committee's recommendation — any change would proceed through a proposed rule with public comment. In short: reviewed and debated, yes; approved for human use, no.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The Epithalon we supply to the research community is a lyophilized powder tested to high purity by HPLC, with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
Epithalon (also spelled Epitalon, and known as AEDG) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was designed to mirror the amino-acid composition of epithalamin, a bovine pineal-gland extract, and was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia.
Epithalon has been studied mainly as a short signaling peptide. In cell-culture research it has been reported to increase telomerase activity and telomere length in human somatic cells, and other studies have examined its influence on melatonin synthesis and circadian regulation. Its precise mechanism of action remains incompletely understood.
No. Epithalon is not an FDA-approved drug. It was reviewed by the FDA Pharmacy Compounding Advisory Committee on July 23–24, 2026 as a candidate for the section 503A bulk-substances list, but that review concerns pharmacy compounding rather than drug approval, and FDA staff had recommended against it. Epithalon sold by Universe Peptide is strictly for in-vitro laboratory research and is not for human or animal use.
A large share of the longevity and anti-aging literature on Epithalon and epithalamin comes from a single research group in St. Petersburg, and many findings are from cell and animal models rather than large, independent human clinical trials. Reviewers therefore treat the anti-aging claims as preliminary until confirmed by broader, replicated research.